Kasabach-Merritt syndrome medical therapy: Difference between revisions
No edit summary |
No edit summary |
||
| Line 10: | Line 10: | ||
If surgery is not possible, certain medications can be used , including | If surgery is not possible, certain medications can be used , including | ||
: | :*[[corticosteroid]]s | ||
: | :*[[alpha-interferon]] | ||
: | :*[[chemotherapy]] (e.g. [[vincristine]]) | ||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
Latest revision as of 17:18, 21 September 2012
|
Kasabach-Merritt syndrome Microchapters |
|
Differentiating Kasabach-Merritt syndrome from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Kasabach-Merritt syndrome medical therapy On the Web |
|
American Roentgen Ray Society Images of Kasabach-Merritt syndrome medical therapy |
|
Risk calculators and risk factors for Kasabach-Merritt syndrome medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Management of KMS, particularly in severe cases, can be complex and require the joint effort of multiple subspecialists. This is a rare disease with no consensus treatment guidelines or large randomized controlled trials to guide therapy.
Medical Therapy
Supportive care
Patients with KMS can be extremely ill and may need intensive care. They are at risk of bleeding complications including intracranial hemorrhage. The thrombocytopenia and coagulopathy are managed with platelet transfusions and fresh frozen plasma, although caution is needed due to the risk of fluid overload and heart failure from multiple transfusions. The possibility of disseminated intravascular coagulation, a dangerous and difficult-to-manage condition, is concerning. Anticoagulant and antiplatelet medications can be used after careful assessment of the risks and benefits.
If surgery is not possible, certain medications can be used , including